Drug Profile
Encochleated capreomycin - Matinas BioPharma
Latest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator Aquarius Biotechnologies
- Developer Matinas BioPharma; National Institute of Allergy and Infectious Diseases
- Class Antibacterials; Antituberculars
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Tuberculosis
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Tuberculosis in USA (PO)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Tuberculosis in USA (PO)
- 30 Jan 2015 Preclinical trials in Tuberculosis in USA (PO)